TY - JOUR
T1 - Andrographis paniculata
T2 - A potential supplementary therapy for cardiovascular diseases - A systematic review of its effects and molecular actions
AU - Eziefule, Oluebube Magnificient
AU - Arozal, Wawaimuli
AU - Wanandi, Septelia Inawati
AU - Dewi, Syarifah
AU - Nafrialdi, null
AU - Saraswati, Meilania
AU - Louisa, Melva
N1 - Publisher Copyright:
© 2024 Journal of Pharmacy & Pharmacognosy Research.
PY - 2024
Y1 - 2024
N2 - Context: Cardiovascular diseases claim the lives of an estimated 17.9 million people worldwide (report by the World Health Organization), yet the drug pipeline compared to some other life-threatening diseases, including cancer and neurological disorders, is low. Aims: To investigate the potential of Andrographis paniculata as a supplementary therapy for cardiovascular diseases based on recent in vivo animal studies. Methods: This study adopted a systematic review approach to analyze preclinical evidence from in vivo animal studies. Three databases (PubMed, Scopus, and Embase) were searched using the keywords "Andrographis paniculata", "cardiovascular disease", "CVD", "heart disease", "cardioprotective", "cardio*", "inflammation", "oxidative stress", "obesity", "lipopolysaccharide", "hypertension", "arrhythmia"and "aortic disease". The search period was from April 20th, 2023, to April 26th, 2023, and included studies published from 2013 to 2023. Only in vivo animal studies were appraised. In contrast, clinical studies, in vitro studies, in silico studies, and review papers were excluded. SYRCLE's risk of bias tool was used to assess the risk of bias. Results: Sixteen eligible in vivo animal studies showed that Andrographis paniculata extracts and isolated bioactive compounds have strong anti-inflammatory and antioxidant effects on cardiovascular diseases. These effects lead to lowering the risk of coronary artery disease and myocardial infarction, easing the effects of bad cardiac remodeling, stopping cardiac hypertrophy, and improving diabetic cardiomyopathy. Although SYRCLE's tool detected some bias, the studies were included since they met the inclusion criteria and had no conflicts of interest. Conclusions: Andrographis paniculata may have the potential to be used as a supplementary therapy for cardiovascular diseases, but more animal studies and clinical trials should be done to establish these findings.
AB - Context: Cardiovascular diseases claim the lives of an estimated 17.9 million people worldwide (report by the World Health Organization), yet the drug pipeline compared to some other life-threatening diseases, including cancer and neurological disorders, is low. Aims: To investigate the potential of Andrographis paniculata as a supplementary therapy for cardiovascular diseases based on recent in vivo animal studies. Methods: This study adopted a systematic review approach to analyze preclinical evidence from in vivo animal studies. Three databases (PubMed, Scopus, and Embase) were searched using the keywords "Andrographis paniculata", "cardiovascular disease", "CVD", "heart disease", "cardioprotective", "cardio*", "inflammation", "oxidative stress", "obesity", "lipopolysaccharide", "hypertension", "arrhythmia"and "aortic disease". The search period was from April 20th, 2023, to April 26th, 2023, and included studies published from 2013 to 2023. Only in vivo animal studies were appraised. In contrast, clinical studies, in vitro studies, in silico studies, and review papers were excluded. SYRCLE's risk of bias tool was used to assess the risk of bias. Results: Sixteen eligible in vivo animal studies showed that Andrographis paniculata extracts and isolated bioactive compounds have strong anti-inflammatory and antioxidant effects on cardiovascular diseases. These effects lead to lowering the risk of coronary artery disease and myocardial infarction, easing the effects of bad cardiac remodeling, stopping cardiac hypertrophy, and improving diabetic cardiomyopathy. Although SYRCLE's tool detected some bias, the studies were included since they met the inclusion criteria and had no conflicts of interest. Conclusions: Andrographis paniculata may have the potential to be used as a supplementary therapy for cardiovascular diseases, but more animal studies and clinical trials should be done to establish these findings.
KW - Andrographis paniculata
KW - animal models
KW - cardiovascular diseases
KW - herbal medicine
KW - inflammation
KW - oxidative stress
UR - http://www.scopus.com/inward/record.url?scp=85188097460&partnerID=8YFLogxK
U2 - 10.56499/jppres23.1841_12.3.487
DO - 10.56499/jppres23.1841_12.3.487
M3 - Review article
AN - SCOPUS:85188097460
SN - 0719-4250
VL - 12
SP - 488
EP - 513
JO - Journal of Pharmacy and Pharmacognosy Research
JF - Journal of Pharmacy and Pharmacognosy Research
IS - 3
ER -